UCB's Cimzia meets in Phase III for non-radiographic axial spondyloarthritis

UCB S.A. (Euronext:UCB) reported in May that Cimzia certolizumab pegol met the primary endpoint in the Phase III C-AXSPAND trial to treat non-radiographic axial spondyloarthritis. Cimzia significantly improved

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE